LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis-Reference-Cited by-同舟云学术

LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis

Published:2023-11 Issue: Volume:384 Page:117117
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Schreuder M.M.,Hamkour S.,Siegers K.E.,Holven K.B.,Johansen A.K.,van de Ree M.A.,Imholz B.,Boersma E.,Louters L.,Bogsrud M.P.,Retterstøl K.,Visseren F.L.J.,Roeters van Lennep J.E.,Koopal C.

Funder

Hartstichting

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference36 articles.

1. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society;Nordestgaard;Eur. Heart J.,2013

2. Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes;Nanchen;Circulation,2016

3. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry;Amrock;Atherosclerosis,2017

4. Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: a retrospective cohort study of the UK Simon Broome register linked to national hospital records;Iyen;Atherosclerosis,2020

5. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC);Collaboration;Lancet,2021

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug interactions in cardiology: focus on statins and their combination with other lipid-lowering drugs;Expert Opinion on Drug Metabolism & Toxicology;2024-09-13

2. Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now?;Expert Review of Cardiovascular Therapy;2024-09

3. Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond;American Journal of Preventive Cardiology;2024-09

4. Statins, but not proprotein convertase subtilisin‐kexin type 9 inhibitors, lower chemerin in hypercholesterolemia via low‐density lipoprotein receptor upregulation;MedComm;2024-08-31

5. Monoclonal Anti-PCSK9 Antibodies: Real-World Data;Journal of Clinical Medicine;2024-08-03